7 May 2020

1) CTF

GML is still trying to collected feedback from Ian Bates on the revised timeline for the deliverables (see HERE).

GML received a request from the Swiss association on the possibility to obtain access to the mapping of the German and the Italian national programmes against CTF (see GML’s email HERE). @ PH – In case you have not yet responded to him yet, please let me know what you think.

2) Policy updates

ICU shortages – COM request

• COM has not answered yet. A follow-up email was sent on Monday.

COM shortages tender – expert for shortage proposal

• Feedback received from PH, SA and TS. All in favour of letting EAHP get involved.

Radiopharmaceuticals

• A call will be held on Monday 11 May at 13.35.

Conference call with EMA

• EMA is available on 14 May at 13.30 CEST. @ PH – Does the agenda (see HERE) cover all items you would like to talk about with EMA? I will confirm the meeting date with EMA and share the information with the rest of the Board in case somebody wants to join.

FIP

• André Bédat Award 2020 | Kees was unfortunately not selected (see feedback HERE)
• Meeting with FIP President | Before COVID a meeting was considered. Should this be postponed until fall 2020? @ PH – maybe a date around the GA could be considered.

Refinitiv request

• Refinitiv (a company many focused on financial markets) reached out to me. I find it’s in between the ‘we should look at it’ and the ‘we should discard it category’. I would like your feedback on the request (see email HERE). Also, IVG would like to know if we should consider them as an exhibitor.

Request from Kees – study concerning parenteral drug guides

• @ PH – JDG shared the following email (see HERE) with me. She asked me to add this to the policy call.

3) Board meeting follow-up

COWI Statement on hazardous drugs

• The COWI Statement was updated (see HERE) and shared with the leads. Feedback is requested from them by 8 May.

Patient safety position paper

• A call was held with the patient safety leads on 30 April. PP, AB and SK are currently collecting information on additional aspects for the paper. A second draft will be prepared in May.

Compounding position paper

• SK is working on the third draft of the position, taking into account the feedback from the Board meeting. An exchange with the compounding leads is foreseen for later in May.

COVID-19 survey

• A draft timeline and the work plan were shared with the lead. Feedback is requested from them by 11 May.

Hazardous drugs business case

• The Board leads are currently discussing the scope of the business case.

Novartis COVID-19 resource centre request

• @ PH and AB – could you provide feedback on the email (see HERE) that I shared with you last week?

Wolters Kluwer

• Wolters Kluwer made a counter offer suggesting to use the jurisdiction of NY. This is also not very ideal. A discussion was started on Microsoft Teams.
• Provided the other Board members agree with the proposal not to engage, would you be fine with not signing the contract with Wolters Kluwer?

4) Consultations – state of play

Due date	Type of consultation	Action
21/05/2020	COM – Beating Cancer Plan Public consultation	Deadline prolonged. Submission next week.
31/05/2020	Consultation on the White Paper on Artificial Intelligence – A European Approach	Draft response shared with leads.
31/05/2020	European Strategy for data	Draft response shared with leads.
?late July?	To be published – Roadmap for COM’s Pharmaceutical Strategy

Next policy call – in 2 weeks on a Wednesday (20 May) due to public holiday on the Thursday? Alternative the week of 25 May could be used.